{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:02:56Z","timestamp":1791349376422,"version":"4.3.1"},"reference-count":67,"publisher":"American Diabetes Association","issue":"12","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,1]]},"abstract":"<jats:p>Type 2 diabetes is a chronic disease with disabling micro- and macrovascular complications that lead to excessive morbidity and premature mortality. It affects hundreds of millions of people and imposes an undue economic burden on populations across the world. Although insulin resistance and insulin secretory defects play a major role in the pathogenesis of hyperglycemia, several other metabolic defects contribute to the initiation\/worsening of the diabetic state. Prominent among these is increased renal glucose reabsorption, which is maladaptive in patients with diabetes. Instead of an increase in renal glucose excretion, which could ameliorate hyperglycemia, there is an increase in renal glucose reabsorption, which helps sustain hyperglycemia in patients with diabetes. The sodium\u2013glucose cotransporter (SGLT) 2 inhibitors are novel antidiabetes agents that inhibit renal glucose reabsorption and promote glucosuria, thereby leading to reductions in plasma glucose concentrations. In this article, we review the long journey from the discovery of the glucosuric agent phlorizin in the bark of the apple tree through the animal and human studies that led to the development of the current generation of SGLT2 inhibitors.<\/jats:p>","DOI":"10.2337\/dc15-0642","type":"journal-article","created":{"date-parts":[[2015,11,25]],"date-time":"2015-11-25T05:39:41Z","timestamp":1448429981000},"page":"2344-2353","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":204,"title":["Sodium\u2013Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport"],"prefix":"10.2337","volume":"38","author":[{"given":"Sunder","family":"Mudaliar","sequence":"first","affiliation":[{"name":"Veterans Affairs Medical Center, San Diego, CA"},{"name":"School of Medicine, University of California, San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Polidori","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Zambrowicz","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc., Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"Henry","sequence":"additional","affiliation":[{"name":"Veterans Affairs Medical Center, San Diego, CA"},{"name":"School of Medicine, University of California, San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2015,11,19]]},"reference":[{"key":"2022031220220065900_B1","first-page":"178","article-title":"Analyse des phloridzins","volume":"15","author":"Petersen","year":"1835","journal-title":"Ann Acad Sci Fr"},{"key":"2022031220220065900_B2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/330379a0","article-title":"Expression cloning and cDNA sequencing of the Na+\/glucose co-transporter","volume":"330","author":"Hediger","year":"1987","journal-title":"Nature"},{"key":"2022031220220065900_B3","first-page":"F459","article-title":"Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter","volume":"263","author":"Wells","year":"1992","journal-title":"Am J Physiol"},{"key":"2022031220220065900_B4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev"},{"key":"2022031220220065900_B5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00232-001-0036-y","article-title":"Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat","volume":"182","author":"Vestri","year":"2001","journal-title":"J Membr Biol"},{"key":"2022031220220065900_B6","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/en.2007-1088","article-title":"Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity","volume":"149","author":"Freitas","year":"2008","journal-title":"Endocrinology"},{"key":"2022031220220065900_B7","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"2022031220220065900_B8","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/SLA.0b013e3181d96e1f","article-title":"Rapid upregulation of sodium-glucose transporter SGLT1 in response to intestinal sweet taste stimulation","volume":"251","author":"Stearns","year":"2010","journal-title":"Ann Surg"},{"key":"2022031220220065900_B9","doi-asserted-by":"crossref","first-page":"G241","DOI":"10.1152\/ajpgi.00310.2001","article-title":"Expression of monosaccharide transporters in intestine of diabetic humans","volume":"282","author":"Dyer","year":"2002","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2022031220220065900_B10","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1152\/ajplegacy.1938.122.3.765","article-title":"The renal tubular reabsorption of glucose in the normal dog","volume":"122","author":"Shannon","year":"1938","journal-title":"Am J Physiol"},{"key":"2022031220220065900_B11","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1152\/ajplegacy.1973.224.3.552","article-title":"Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs","volume":"224","author":"Vick","year":"1973","journal-title":"Am J Physiol"},{"key":"2022031220220065900_B12","first-page":"F406","article-title":"Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule: evidence from vesicle studies","volume":"242","author":"Turner","year":"1982","journal-title":"Am J Physiol"},{"key":"2022031220220065900_B13","doi-asserted-by":"crossref","first-page":"e30555","DOI":"10.1371\/journal.pone.0030555","article-title":"Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models","volume":"7","author":"Liang","year":"2012","journal-title":"PLoS One"},{"key":"2022031220220065900_B14","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.2337\/dc12-2391","article-title":"Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study","volume":"36","author":"Polidori","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031220220065900_B15","doi-asserted-by":"crossref","first-page":"E867","DOI":"10.1210\/jc.2012-4205","article-title":"Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus","volume":"98","author":"Polidori","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031220220065900_B16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.12459","article-title":"Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data","volume":"17","author":"Del Prato","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"2022031220220065900_B17","doi-asserted-by":"crossref","first-page":"E117","DOI":"10.1152\/ajpendo.00439.2012","article-title":"Improved glycemic control in mice lacking Sglt1 and Sglt2","volume":"304","author":"Powell","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031220220065900_B18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2337\/db11-1029","article-title":"Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion","volume":"61","author":"Gorboulev","year":"2012","journal-title":"Diabetes"},{"key":"2022031220220065900_B19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1385\/CBB:36:2-3:115","article-title":"Molecular basis for glucose-galactose malabsorption","volume":"36","author":"Wright","year":"2002","journal-title":"Cell Biochem Biophys"},{"key":"2022031220220065900_B20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1124\/jpet.113.203364","article-title":"LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium\/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose","volume":"345","author":"Powell","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"2022031220220065900_B21","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s00125-012-2585-2","article-title":"Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion","volume":"55","author":"Parker","year":"2012","journal-title":"Diabetologia"},{"key":"2022031220220065900_B22","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.coph.2013.08.013","article-title":"Molecular mechanisms of incretin hormone secretion","volume":"13","author":"Ezcurra","year":"2013","journal-title":"Curr Opin Pharmacol"},{"key":"2022031220220065900_B23","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1172\/JCI100559","article-title":"The action of Phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man","volume":"12","author":"Chasis","year":"1933","journal-title":"J Clin Invest"},{"key":"2022031220220065900_B24","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1172\/JCI113157","article-title":"Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats","volume":"80","author":"Rossetti","year":"1987","journal-title":"J Clin Invest"},{"key":"2022031220220065900_B25","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1172\/JCI112981","article-title":"Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats","volume":"79","author":"Rossetti","year":"1987","journal-title":"J Clin Invest"},{"key":"2022031220220065900_B26","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.2337\/diabetes.48.9.1794","article-title":"T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes","volume":"48","author":"Oku","year":"1999","journal-title":"Diabetes"},{"key":"2022031220220065900_B27","doi-asserted-by":"crossref","first-page":"G946","DOI":"10.1152\/ajpgi.00286.2014","article-title":"Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release","volume":"308","author":"Dobbins","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2022031220220065900_B28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2022031220220065900_B29","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1021\/jm200049r","article-title":"Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors","volume":"54","author":"Mascitti","year":"2011","journal-title":"J Med Chem"},{"key":"2022031220220065900_B30","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1021\/jm901893x","article-title":"(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment","volume":"53","author":"Kakinuma","year":"2010","journal-title":"J Med Chem"},{"key":"2022031220220065900_B31","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/clpt.2012.58","article-title":"LX4211, a dual SGLT1\/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial","volume":"92","author":"Zambrowicz","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2022031220220065900_B32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2337\/dc14-0890","article-title":"Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031220220065900_B33","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/dom.12418","article-title":"Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study","volume":"17","author":"Sha","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"2022031220220065900_B34","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.metabol.2014.07.003","article-title":"Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial","volume":"63","author":"Stein","year":"2014","journal-title":"Metabolism"},{"key":"2022031220220065900_B35","article-title":"Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)","author":"Pieber","journal-title":"Diabetes Obes Metab"},{"key":"2022031220220065900_B36","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc13-2955","article-title":"Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study","volume":"38","author":"Henry","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031220220065900_B37","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2337\/dc14-2806","article-title":"Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes","volume":"38","author":"Sands","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031220220065900_B38","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"2022031220220065900_B39","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00125-014-3196-x","article-title":"Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes","volume":"57","author":"Polidori","year":"2014","journal-title":"Diabetologia"},{"key":"2022031220220065900_B40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/dia.2013.0167","article-title":"Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin","volume":"16","author":"Mudaliar","year":"2014","journal-title":"Diabetes Technol Ther"},{"key":"2022031220220065900_B41","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"key":"2022031220220065900_B42","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat Med"},{"key":"2022031220220065900_B43","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.4158\/EP14489.OR","article-title":"Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy","volume":"20","author":"Hansen","year":"2014","journal-title":"Endocr Pract"},{"key":"2022031220220065900_B44","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/dom.12322","article-title":"Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus","volume":"16","author":"Sha","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2022031220220065900_B45"},{"key":"2022031220220065900_B46"},{"key":"2022031220220065900_B47"},{"key":"2022031220220065900_B48","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2022031220220065900_B49","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"2022031220220065900_B50","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/dom.12073","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks\u2019 treatment with empagliflozin once daily in patients with type 2 diabetes","volume":"15","author":"Heise","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2022031220220065900_B51","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2022031220220065900_B52","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"2022031220220065900_B53","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"Yale","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2022031220220065900_B54","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031220220065900_B55","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"2022031220220065900_B56","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/ki.2013.451","article-title":"Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering","volume":"86","author":"Gilbert","year":"2014","journal-title":"Kidney Int"},{"key":"2022031220220065900_B57","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"2022031220220065900_B58","unstructured":"Boehringer Ingelheim. BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2015. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01131676?term=empagliflozin+and+cardiovascular&rank=1"},{"key":"2022031220220065900_B59","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","article-title":"Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial","volume":"166","author":"Neal","year":"2013","journal-title":"Am Heart J"},{"key":"2022031220220065900_B60","unstructured":"AstraZeneca. Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2015. Available from http:\/\/clinicaltrials.gov\/show\/NCT01730534"},{"key":"2022031220220065900_B61","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.clinthera.2013.06.011","article-title":"Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects","volume":"35","author":"Zambrowicz","year":"2013","journal-title":"Clin Ther"},{"key":"2022031220220065900_B62","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.clinthera.2013.01.010","article-title":"Effects of LX4211, a dual SGLT1\/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes","volume":"35","author":"Zambrowicz","year":"2013","journal-title":"Clin Ther"},{"key":"2022031220220065900_B63","unstructured":"U.S. Food and Drug Administration. Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood [article online], 2015. Available from http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm446845.htm. Accessed 18 July 2015"},{"key":"2022031220220065900_B64","unstructured":"European Medicines Agency. Review of diabetes medicines called SGLT2 inhibitors started [article online], 2015. Available from http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/referrals\/SGLT2_inhibitors\/human_referral_prac_000052.jsp&mid=WC0b01ac05805c516f. Accessed 18 July 2015"},{"key":"2022031220220065900_B65","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031220220065900_B66","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2015-1884","article-title":"SGLT2 inhibitors may predispose to ketoacidosis","author":"Taylor","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031220220065900_B67","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","article-title":"Possible adverse effects of SGLT2 inhibitors on bone","volume":"3","author":"Taylor","year":"2015","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/38\/12\/2344\/622771\/dc150642.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/38\/12\/2344\/622771\/dc150642.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T22:18:27Z","timestamp":1647123507000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/38\/12\/2344\/28967\/Sodium-Glucose-Cotransporter-Inhibitors-Effects-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,19]]},"references-count":67,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,11,19]]},"published-print":{"date-parts":[[2015,12,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc15-0642","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,19]]}}}